603193.SS SHH
Runben Biotechnology
1W: -1.9%
1M: -2.1%
3M: +5.2%
YTD: -15.3%
1Y: -35.4%
¥20.25 ($3.02)
+0.25 (+1.25%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$1.3B
+27.6% ▲
5Y CAGR: +36.5%
Gross Profit
$767M
+31.7% ▲
5Y CAGR: +38.5%
Operating Income
$347M
+31.2% ▲
5Y CAGR: +52.8%
Net Income
$300M
+32.8% ▲
5Y CAGR: +53.1%
EPS (Diluted)
$0.74
+15.6% ▲
5Y CAGR: +1.1%
EBITDA
$373M
+28.7% ▲
5Y CAGR: +45.1%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $443M | $582M | $856M | $1.0B | $1.3B |
| YoY Growth | +58.9% | +31.5% | +47.1% | +20.7% | +27.6% |
| Cost of Revenue | $210M | $273M | $392M | $451M | $551M |
| Gross Profit | $233M | $309M | $464M | $582M | $767M |
| Gross Margin | 52.5% | 53.0% | 54.2% | 56.3% | 58.2% |
| R&D Expenses | $11M | $14M | $20M | $26M | $35M |
| SG&A Expenses | $81M | $120M | $224M | $282M | $342M |
| Operating Expenses | $120M | $170M | $282M | $317M | $420M |
| Operating Income | $110M | $141M | $186M | $265M | $347M |
| Operating Margin | 24.9% | 24.2% | 21.7% | 25.6% | 26.3% |
| Interest Expense | $35K | $2M | $857K | $353K | $132K |
| Income Before Tax | $110M | $142M | $188M | $268M | $352M |
| Tax Expense | $16M | $21M | $28M | $42M | $52M |
| Net Income | $95M | $121M | $160M | $226M | $300M |
| Net Margin | 21.4% | 20.7% | 18.7% | 21.9% | 22.8% |
| EPS (Diluted) | $0.23 | $0.30 | $0.40 | $0.64 | $0.74 |
| EBITDA | $119M | $153M | $209M | $290M | $373M |
| Shares Outstanding | 405M | 405M | 405M | 353M | 406M |